ReBlood Rx

Another month down, and ReBlood Rx is making every day count! Our team is pushing forward on all fronts—manufacturing, fundraising, and strategic partnerships—all with one goal: bringing our innovation to those who need it most! ???Big News: ReBlood Rx was selected as a?Top 40 company?for the?Technology & National Security Conference at Harvard Business School—and we’re gearing up for the chance to win up to?$100,000! ???Achievements: We’re in discussions with three contract manufacturers across the country to scale production and reach commercial volumes. If you have experience in contract manufacturing, especially in biologics, we’d love to hear from you! ???Opportunities: We’re actively pitching to investors and making connections to close our funding round. If you or someone in your network is interested in reviewing our pitch deck, let’s talk! ReBlood Rx is grateful for our mentors, advisors, partners, and supporters who make this journey possible. Let’s keep moving forward together.?To stay updated on our progress follow us on LinkedIn and check out our full newsletter below! #ReBloodRx #HealthTech #Innovation #StartupLife #Biotech

The first month of 2025 is behind us and we’re excited to share the latest updates and milestones from ReBlood Rx. Thank you for your continued support and guidance—we couldn’t do this without you! ???Big News: ReBlood Rx has secured funding from rpv, a deep tech venture firm that focuses on early-stage scientifically intensive ventures! We are grateful and excited to work with Arkady Kulik and rpv towards closing our Seed Round soon! ???Achievements: We recently applied to be part of the 2025 Cool Companies program that matches life sciences startups with quality venture capital. Additionally, we’re working with our regulatory advisor to prepare for an FDA presubmission meeting and continuing discussions with a contract manufacturer to meet preclinical demand this year. ???Opportunities: We’re seeking insights into blood bank logistics and manufacturing expertise, especially in biologics. If you or someone in your network has experience, we’d love to connect. We’re also open to feedback on our pitch deck and appreciate recommendations for grants in the DoD, NSF, or NIH ecosystems or accelerators that could support our growth. To stay updated on our progress, check out our full newsletter below! #ReBloodRx #HealthTech #Innovation #StartupLife #Biotech

Happy New Year from?ReBlood Rx! We hope everyone had a joyous and restful holiday season. As we kick off 2025, we’re excited to share the latest updates and milestones achieved by our team. Thank you for your continued support and guidance—we couldn’t do this without you! ???Big News: ReBlood Rx has started exciting conversations with blood banks across the United States to enhance our understanding of logistics and strengthen our supply chain as we move closer to manufacturing readiness. ???Achievements: We recently applied to the VelocityTX Incubator, which supports early-stage bioscience companies in achieving breakthroughs. Additionally, we’re working with our regulatory advisor to prepare for an FDA presubmission meeting and continuing discussions with a contract manufacturer to meet preclinical demand this year. ???Opportunities: We’re seeking insights into blood bank logistics and manufacturing expertise, especially in biologics. If you or someone in your network has experience, we’d love to connect. We’re also open to feedback on our pitch deck and appreciate recommendations for grants in the DoD, NSF, or NIH ecosystems or accelerators that could support our growth. To stay updated on our progress, check out our full newsletter below! #ReBloodRx #HealthTech #Innovation #StartupLife #Biotech

As the holiday season is in full swing, ReBlood Rx reflects on an incredible year of progress and innovation. We are immensely grateful for our hardworking team, the invaluable guidance of our mentors, and the unwavering support of our friends, family, and professional network. Thank you for helping us make it all possible! ??Big News: We are thrilled to announce that ReBlood Rx has passed IC1 with a leading biotech venture fund, placing us in the top 2% of companies they’ve evaluated! This is a huge milestone as we continue our journey toward securing seed funding. ??Achievements:?We’ve successfully opened an Investigational New Animal Drug (INAD) file with the FDA and are preparing for a presubmission meeting. ??Opportunities:?We’re seeking insights into the logistics of blood banks. If you or someone in your network can share expertise, we’d love to connect!?Additionally, we are looking for manufacturing experts, especially in biologics. Let us know if you’re available to help! To learn more and stay updated, check out our full newsletter below! #ReBloodRx #HealthTech #Innovation #StartupLife #Biotech

Thanksgiving is fast approaching and ReBlood Rx is thankful for the hard work of every member of our team, the guidance of our mentors and advisors, and the support of our family, friends and network! ?? Big News: Our CEO, Carlos J. Munoz, had the opportunity to pitch to Angels and Managing Partners during an investor roadshow put on by 757 Collab! ?? Achievements: Our team is extremely excited to announce that we are in conversations with Cannon Virginia to explore the potential of a contract manufacturing partnership! ?? Opportunities: With investor pitching in full swing, if you or a colleague are interested in scheduling a meeting or would like to review our pitch, please reach out to us! To read the full newsletter, please see below! #ReBloodRx #HealthTech #Innovation #StartupLife

So excited to kick off the 6th annual IGE UC San Diego Showcase with over 25 Startups tabling. This year’s theme is “Game- Changing Impact” with a focus on our MedTech Startups. Leading the event is an invite-only investor preview with 9 investor-ready startups pitching. Investable Startups Veera GolTech ReBlood Rx Mercury Alert AI AIR Surgical, Inc. Vesica AI Channel Robotics Kato Medical Limber Prosthetics & Orthotics Dennis Abremski Rebecca Deller Sujit Dey Albert "Al" P. Pisano, Ph.D. Sinan G?lhan Carlos J. Munoz Ji Lee Dimitri Schreiber Albert Liu, PhD Michael Yip Philip A. Weissbrod, MD Joshua Pelz Albert Hill Sai Zhou Mridu Sinha Arshan Ommid #igemedtech #medtech #innovations

Exciting News!??? ReBlood Rx is hitting the road for a week of pitch events as part of the 757 Accelerate Investor Roadshow! We're thrilled to be joining eight other startups to present at?five investor events, starting Monday,?October 14th?in North Carolina and wrapping up Thursday,?October 17th?in Virginia. Our goal is to engage?100 investors?over the week, so if you're an accredited investor—or know someone who is—this is a fantastic opportunity to hear our pitch and connect! Register today?and get all the details here: https://lnkd.in/gSVJbk99 Can’t make it? No worries! Reach out to us directly, and we’d be happy to schedule a time to share our vision. ?? #757Accelerate #ReBloodRx #HealthTech #Startup #Innovation

Presenting a roundup of incredible achievements from our trailblazing alumni companies! Their milestones and inspiring success stories are not to be missed. Check out the highlights in the comments below, and don’t forget to subscribe to our new #SustainabilityInnovators monthly newsletter for more! ? ?? AirVitalize Innovations raises $155,000+ in non-dilutive funding, files an international patent, and secures a paid winter pilot for Fairbanks. ?? Gradible participates in the Green Sports Alliance Summit. ?? Founder of SEED - Sustainable Entrepreneurial Ecosystem Development, Sabrina Williams ??, gets featured in Bold Journey. ?? RxPost gets selected as a top 10 finalist for the Women Founders Network 2024 Fast Pitch Event. ?? ReBlood Rx accepted into 757 Accelerate’s Cohort 7. ?? Kind Designs gets featured on the PodBean podcast in The Contrarian Tide-Turner: Anya Freeman on Leading Kind Designs. ?? Apptronik demonstrates humanoid robot Apollo at IMTS. ?? Aquaria CEO Brian Sheng gets featured in The Impact At Scale podcast. ?? RabbleHealth partners with Asthma and Allergy Foundation of America to lead advocacy on implementation science & patient empowerment in asthma. ?? Suma recognized in Pacific Coast Business Times 40 Under 40, Prime Health Innovation Challenge, and Anthem Awards. ?? Get the full scoop here: https://lnkd.in/e6peYqkw ?? Don’t miss out! Subscribe to our newsletter: https://lnkd.in/gtcdE6J2 Let’s amplify these wins together! ?? #Sustainability #Innovation #ClimateAction #HealthTech #ClimateTech #LartaInstitute

How can we revolutionize emergency care in environments where traditional blood transfusions aren't possible? Our #HealLA 2024 cohort member, ReBlood Rx, is developing polymerized hemoglobin-based oxygen carriers (HBOCs) designed to improve remote damage control resuscitation (RDCR). This groundbreaking technology, led by founders Carlos J. Munoz, CEO, and Christopher Caballero, COO, targets environments where traditional crystalloids fall short due to their lack of oxygen-carrying capacity, offering a practical substitute for blood transfusions. ?? Carlos J. Munoz shares, "In the next 5-10 years, ReBlood Rx envisions a fully cleared FDA product for pre-hospital care situations where blood is needed but not available, increasing medical capabilities for people living in rural environments." This innovation has the potential to revolutionize field medicine, eliminating the need for refrigeration, crossmatching, and supply issues, ultimately enhancing the care provided by combat medics and pre-hospital care providers. We are proud to support ReBlood Rx, as they aim to transform emergency care and increase accessibility for all. ?? ____ HealLA provides a free, nine-month accelerator program aimed at nurturing and scaling innovations that address healthcare insecurity, inequities, and lack of preventive care. The HealLA Bioscience and Healthcare Accelerator is supported by esteemed partners such as the California Office of the Small Business Advocate (CalOSBA), U.S. Small Business Administration (SBA), Gilead Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, BioscienceLA, Cedars-Sinai, Keck School of Medicine of the University of Southern California, UCLA Technology Development Group, Biocom California, MedTech Color, Consortium for Technology & Innovation in Pediatrics (CTIP), California State University, Los Angeles, City of Hope, BioLabs, Rio Hondo College, Alliance for Southern California Innovation, Rancho Los Amigos National Rehabilitation Center, Keck Graduate Institute, WuXi Biologics. Learn more about the HealLA Bioscience and Healthcare Accelerator: https://lnkd.in/gi94ZB_f Discover the 2024 HealLA cohort: https://lnkd.in/gKRdHdzm #EmergencyCareInnovation #HBOCs #FieldMedicine #RemoteResuscitation #HealthcareInnovation #HealLA